Drug intelligence / Profile preview

F(ab')2 antivenom of Daboia russelii siamensis

Development stage
Phase 1
Lead developer
Queen Saovabha Memorial Institute
Modality
Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

F(ab')2 antivenom of Daboia russelii siamensis is a species-specific immunotherapeutic product composed of purified F(ab')2 antibody fragments derived from the plasma of animals (typically horses) immunized with the venom of the Eastern Russell’s viper (Daboia russelii siamensis). The primary mechanism is passive immunization—these antibody fragments bind and neutralize toxic components in the snake venom, thereby preventing or reversing systemic envenoming effects such as coagulopathy, neurotoxicity, and tissue damage. This monovalent antivenom is specifically formulated to target antigenic proteins present in D. r. siamensis venom and has demonstrated efficacy against geographically diverse venoms from Thailand and Indonesia[3]. It does not contain the Fc portion of IgG antibodies, reducing risk for certain immune reactions compared to whole IgG preparations.

Other names
F(ab')2 antivenom for Daboia russelii siamensisF(ab')2 anti-Daboia siamensis antivenomDsMAV-Thailand
02

Targets

Snaclec (Daboia russelii siamensis C-type lectin-like venom protein)DrS-Kunitz (Daboia russelii siamensis Kunitz-type serine protease inhibitor)LAAO (L-amino-acid oxidase (Daboia siamensis))PCV2 Cap (Porcine circovirus type 2 capsid protein)svPLA2 (Snake venom phospholipase A2)SVMP (Daboia russelii siamensis snake venom metalloproteinase)SVSP (Snake venom serine protease)

Beyond the preview

Go deeper on F(ab')2 antivenom of Daboia russelii siamensis.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on F(ab')2 antivenom of Daboia russelii siamensis.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call